Bio-Works Technologies (BIOWKS) Q4 2025 earnings summary

Executive summary

• Achieved record net sales and order intake in 2025, with strong growth across all regions and major customer deliveries, especially in Europe.

• Operating profit and cash flow improved significantly, with the fourth quarter approaching break-even.

• Strategic partnerships and new product launches expanded market reach and customer base.

Financial highlights

• Net sales for Q4 2025 were 23.7 MSEK, up from 2.6 MSEK year-over-year; full-year net sales reached 62.5 MSEK, up from 25.5 MSEK.

• Operating profit for Q4 improved to -0.9 MSEK from -13.8 MSEK; full-year operating profit was -17.5 MSEK, up from -38.0 MSEK.

• Q4 profit was 1.4 MSEK, aided by a 2.0 MSEK tax reversal; full-year profit was -15.2 MSEK, compared to -37.4 MSEK.

• Cash flow from operating activities for the year improved to -18.8 MSEK from -43.2 MSEK; cash and cash equivalents at year-end were 34.9 MSEK.

• Earnings per share for the year were -0.17 SEK, up from -0.75 SEK.

Outlook and guidance

• Order book at year-end was 32.5 MSEK, providing a stable foundation for 2026.

• Ongoing investments in manufacturing and commercialization expected to support continued growth and profitability.